New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
12:01 EDTRAX, VZ, XON, TMUS, GOOGL, FDX, DOW, DG, AZN, AMGN, FNSR, ALLY, MDLZThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
News For RAX;ALLY;FNSR;AMGN;AZN;DG;DOW;FDX;GOOGL;TMUS;XON;VZ;MDLZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
September 16, 2014
16:56 EDTRAXRackspace says goal during evaluation was maximizing shareholder value
Subscribe for More Information
16:53 EDTRAXRackspace says will not do share buybacks at this time
Company says wants to remain flexible and that will consider share buybacks in the future There are acquisitions out there that they may prefer doing in cash. Comments from Rackspace conference call.
16:26 EDTRAXRackspace says on track for 'strong' Q3, 'comfortable' with guidance ranges
Subscribe for More Information
16:23 EDTRAXRackspace falls 17.5% after ending review, deciding to stay independent
Subscribe for More Information
16:22 EDTRAXRackspace to remain independent, ends review of alternatives
Subscribe for More Information
16:20 EDTRAXRackspace to remain independent, ends review of alternatives
Subscribe for More Information
16:17 EDTRAXRackspace names Taylor Rhodes as CEO
Subscribe for More Information
16:00 EDTFDXFedEx technical comments ahead of results
Shares have outperformed in the last three months, trading up over 10%. The trading range in the same period has been contained between $146 at the low and $155 at the top, the latter being close to the life high. On stronger than expected news, the shares could easily top life highs, opening up a range of $156 to $165 depending on the degree of positive surprise. Without resistance, there may be room for an upside surprise in price. If the shares break the low at $146, the technical picture for the stock could change considerably. A break below $145 would put the current uptrend in jeopardy. Additional supports below are at $140.27 and $135.49 on an extreme move lower.
15:14 EDTFDXNotable companies reporting before tomorrow's open
Subscribe for More Information
14:39 EDTFDXFedEx September 155 straddle priced for 3% move into Q1
Subscribe for More Information
14:33 EDTAZNNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
12:37 EDTAZNNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
11:51 EDTAZNOECD looks to close tax loopholes with new proposals
Subscribe for More Information
10:19 EDTAZNFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
08:18 EDTVZFCC to hold a roundtable
Subscribe for More Information
08:00 EDTAZNFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:49 EDTMDLZBofA/Merrill to hold a conference
Subscribe for More Information
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use